NeOnc Technologies Holdings Inc(US:NTHI) Globenewswire·2025-11-14 21:01Core Insights - NeOnc Technologies Holdings, Inc. reported significant clinical progress and financial results for Q3 2025, highlighting advancements in its CNS oncology pipeline and strategic partnerships [1][5][6] Clinical Pipeline Progress - NEO100-01, an intranasal therapy for malignant recurrent WHO Grade 3/4 IDH1 Astrocytoma, showed a 21% response rate compared to a historical average of less than 8% [3][6] - 44% of patients achieved six-month progression-free survival, significantly higher than the historical range of 21-31% [3][6] - The company secured $2.5 million in STTR grants from NIH to advance NEO212 for gliomas and leukemia, indicating strong scientific validation [3][6] - NuroMENA, the UAE-based subsidiary, established a $50 million strategic partnership with Quazar Investment to enhance collaboration in brain cancer treatment [3][6] Financial Results - General and administrative expenses increased to $903,000 from $244,000 in Q3 2024, attributed to expanded marketing and partnership costs [9] - Research and development expenses decreased to $715,000 from $957,000 in Q3 2024, reflecting active management of trial sites and patient recruitment [9] - The net loss for Q3 2025 was $8.6 million, or $0.45 per diluted share, compared to a net loss of $2.2 million, or $0.12 per diluted share in Q3 2024 [9] Strategic Developments - The company appointed Amir Heshmatpour as CEO to lead the next phase of clinical and corporate growth [3][6] - NeOnc joined the Russell Microcap® Index, increasing visibility among institutional investors [3][6] - The company executed an agreement to acquire advanced AI and 3D bioprinting intellectual property, expanding its technological capabilities [3][6] Upcoming Milestones - Full Phase 2a enrollment for NEO100 has been completed, with top-line data readout expected in May 2026 [3][10] - The final patient cohort in Phase I for NEO212 is on track to complete dosing in 2025 [9][10]